Evidence map›Paper›PMID 41680690›Full record

ArticleBMC ophthalmology2026

Investigation of pan-immune inflammatory value in patients with age-related macular degeneration.

Selma Mesen, Merve Nur Yılmaz

Abstract read
In one paragraph

Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Selma MesenOphthalmology Department, Kahramanmaraş Sutcu Imam University Health Practice and Research Hospital, Kahramanmaraş, TR 46040, Turkey. drselmamesen@gmail.com.ORCID http://orcid.org/0000-0002-5556-8635
Merve Nur YılmazOphthalmology Department, Tatvan State Hospital, Bitlis, TR 46040, Turkey.ORCID http://orcid.org/0009-0002-9600-9060

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to evaluate the systemic pan-immune inflammatory value (PIV) in wet and dry cases of age-related macular degeneration.

methodsPatients diagnosed with AMD between 2020 and 2025 were retrospectively identified. The participants were divided into the wet AMD, dry AMD, and control groups. Their complete blood count (CBC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride, and C-reactive protein data were obtained. Neutrophil-to-lymphocyte, monocyte-to-lymphocyte, platelet-to-lymphocyte, and neutrophil-to-HDL ratios were calculated. The PIV was calculated as follows: (neutrophil × platelet × monocyte/lymphocyte count). The central macular and subfoveal choroidal thicknesses were measured manually from the spectral domain optical coherence tomography (OCT) images.

resultsOf the 72 cases included in the study, 25 were wet AMD, 26 were dry AMD, and 21 were controls. According to the statistical analysis, the white blood cell count (7.89 ± 1.82 vs. 6.66 ± 1.75), neutrophil count (5.02 ± 1.42 10

conclusionIn our study, the PIV was statistically significantly higher in the wet AMD group than in the dry AMD and control groups. Obtaining CBC data is a highly cost-effective and practical method for calculating PIV. PIV calculation can be helpful in the follow-up of patients with AMD, especially those at high risk of converting from dry AMD to wet AMD.

Indexed as

Geographic AtrophyInflammationMacular DegenerationWet Macular DegenerationAgedAged, 80 and overBlood Cell CountBlood PlateletsC-Reactive ProteinFemaleHumansLeukocyte CountLymphocytesMaleMonocytesNeutrophilsC-Reactive ProteinComplete blood countDry-type age-related macular degenerationPan-immune inflammatory valueWet-type age-related macular degeneration

Identifiers

PMID41680690
PMCPMC12997720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.